denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Bristol Myers Squibb; Jazz Pharmaceuticals; Kura Oncology, Inc.; Rigel Pharmaceuticals, Inc.; and Syndax Pharmaceuticals, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical trials, Acute Myeloid Malignancies, AML, Combination therapy, Drug development, Clinical Research, Education, Patient-reported outcomes, Diseases, Therapy sequence, Real-world evidence, Treatment Considerations, Adverse Events, Myeloid Malignancies
Hematology Disease Topics & Pathways:
Research, Clinical trials, Acute Myeloid Malignancies, AML, Combination therapy, Drug development, Clinical Research, Education, Patient-reported outcomes, Diseases, Therapy sequence, Real-world evidence, Treatment Considerations, Adverse Events, Myeloid Malignancies
Friday, December 6, 2024: 11:00 AM-2:00 PM
Ballroom 20CD
(San Diego Convention Center)
Chair:
Naval Daver, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Daver: Celgene: Consultancy; Trillium: Consultancy, Research Funding; Arog: Consultancy; Astellas: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Glycomimetics: Research Funding; Syndax: Consultancy; Jazz: Consultancy; Shattuck Labs: Consultancy; FATE Therapeutics: Other: Consulting Fees, Research Funding; Trovagene: Research Funding; Agios: Consultancy; KITE: Research Funding; Gilead: Consultancy, Research Funding; Hanmi: Research Funding; Pfizer: Consultancy, Research Funding; Menarini Group: Consultancy; Novimmune: Research Funding; Novartis: Consultancy; Genentech: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy, Research Funding.
Speakers:
Gail J. Roboz, MD, Weill Cornell Medicine/New York Presbyterian Hospital
,
Amir T. Fathi, MD, Massachusetts General Hospital Cancer Center
,
Joshua F. Zeidner, MD, University of North Carolina
and
Jessica Altman, MD, Professor of Medicine, Hematology Oncology Division, Northwestern University
Disclosures:
Roboz: Janssen: Research Funding; OncoPrecision: Current holder of stock options in a privately-held company, Honoraria; AbbVie, Amgen, Astrazeneca, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses pharma, Geron, GSK, Glycomimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, Oncoverity: Consultancy; Novartis, Pfizer, Roche, GlaxoSmithKline, BMS, Syndax, Rigel: Consultancy. Fathi: Takeda: Consultancy; Orum: Consultancy; Astellas: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Agios: Ended employment in the past 24 months; AbbVie, BMS/Celgene, and Agios/Servier: Research Funding; MorphoSys: Consultancy; Kite: Consultancy; Rigel: Consultancy; Pfizer: Consultancy; Daiichi Sankyo: Consultancy; Genentech: Honoraria; Mablytics: Consultancy; BMS/Celgene: Consultancy; Autolus: Consultancy; Amgen: Consultancy; Menarini Group: Consultancy; Remix: Consultancy; Ispen: Consultancy; Gilead: Consultancy; Abbvie: Consultancy, Research Funding; Novartis: Consultancy; ImmunoGen: Consultancy; EnClear: Consultancy; Ipsen: Consultancy; Foghorn, Blueprint Medicines, Kura, Trillium: Honoraria; PureTech: Consultancy; Forma: Consultancy; AstraZeneca: Honoraria.
To maximize the clinical outcomes for individual patients, practicing healthcare professionals must have mastered how to leverage the evidence and possess the competence to apply treatment guidelines and the latest emerging data with regard to the many recent approvals in this therapeutic space. To ensure competence and improve patient outcomes, strategic educational programming is necessary. This program will focus on how to best leverage emerging evidence for currently available therapies and proactively manage and mitigate treatment-related toxicities.
See more of: Friday Satellite Symposia